Ensartinib
Medication
From Wikipedia, the free encyclopedia
Ensartinib, sold under the brand name Ensacove, is an anti-cancer medication used for the treatment of non-small cell lung cancer.[1] Ensartinib is an Anaplastic lymphoma kinase (ALK) inhibitor used as the salt ensartinib hydrochloride.[1] It is taken by mouth.[1]
| |
| Clinical data | |
|---|---|
| Trade names | Ensacove |
| Other names | X-396 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625004 |
| License data |
|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.306.918 |
| Chemical and physical data | |
| Formula | C26H27Cl2FN6O3 |
| Molar mass | 561.44 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The most common adverse reactions include rash, musculoskeletal pain, constipation, cough, pruritis, nausea, edema, pyrexia, and fatigue.[2]
Ensartinib was approved for medical use in the United States in December 2024.[1][2][3][4]
Medical uses
History
Efficacy was evaluated in eXALT3 (NCT02767804), an open-label, randomized, active-controlled, multicenter trial in 290 participants with locally advanced or metastatic ALK-positive non-small cell lung cancer who had not previously received an ALK-targeted therapy.[2] Participants were randomized 1:1 to receive ensartinib or crizotinib.[2]
